Eli Lilly: FDA priority review for Selpercatinib
(CercleFinance.com) - Eli Lilly has announced that the US FDA has granted priority review status to Selpercatinib's New Drug Application (NDA).
This drug treats patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer.
"This represents an important step toward providing a new precision therapy for people living with certain RET-driven cancers," said Anne White, president of Lilly Oncology.
"Combined with the recent opening of our two Phase 3 selpercatinib clinical trials, we are thrilled with the positive momentum of this program and hope to deliver a practice-changing treatment to patients with RET-driven cancers as soon as possible."
Copyright (c) 2020 CercleFinance.com. All rights reserved.